Menu
Not yet recruiting NCT07609667

SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma

Phase II Interventional Gastroesophageal Junction Adenocarcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Tislelizumab, SKB315 for injection, Capecitabine.
Who it may be relevant to
Registry conditions: Gastroesophageal Junction Adenocarcinoma. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase II Study Evaluating the Efficacy and Safety of SKB315 Combination Therapy in Claudin18.2 Positive Patients With Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Overview

This study is a multicenter,open-label,randomized, phase II clinical study conducted in China. The purpose of this study is to evaluate the efficacy of SKB315 plus PD-1 inhibitor ±capecitabine in patients with Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Detailed description

This study is a multicenter,open-label,randomized, phase II clinical study conducted in China. The purpose of this study is to evaluate the efficacy of SKB315 plus PD-1 inhibitor ±capecitabine in patients with Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This study will also evaluate efficacy, physical function, safety, and tolerability of SKB315 combination, as well as Pharmacokinetics (PK) of SKB315 and the immunogenicity profile of SKB315 will be evaluated as well.

Interventions

  • Drug Tislelizumab
    Tislelizumab will be administered as the protocol described
  • Drug SKB315 for injection
    Tislelizumab will be administered as the protocol described
  • Drug Capecitabine
    Capecitabine will be taken orally as the protocol described

Primary outcome measures

  • Objective Response Rate (ORR) [Time frame: up to 2 years]
Secondary outcome measures (6)
  • Duration of Response (DOR) [Time frame: up to 2 years]
  • Progression Free Survival (PFS) [Time frame: up to 2 years]
  • Overall Survival (OS) [Time frame: up to 2 years]
  • Safety and tolerability assessed by adverse events (AEs) [Time frame: Until 90 days after the end of treatment]
  • Time to Response (TTR) [Time frame: up to 2 years]
  • Disease Control Rate (DCR) [Time frame: up to 2 years]

Eligibility criteria

Inclusion criteria

  • Locally advanced unresectable or metastatic gastric cancer (GC) or gastroesophageal junction (GEJ) carcinoma and have histologically confirmed adenocarcinoma
  • No previous systemic therapy for locally advanced unresectable or metastatic gastric/GEJ cancer.
  • Consent to provide archival or fresh tumor tissue slides for immunohistochemistry (IHC) assessment, and advanced solid tumors with Claudin 18.2 and PD-L1 expression as determined by IHC;
  • Presence of at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;
  • Eastern Cooperative Oncology Group (ECOG) score of 0 or 1;
  • Estimated survival ≥ 3 months as judged by the investigator;
  • Adequate organ and bone marrow function (no blood components and cytokines are allowed within 2 weeks prior to the first dose) ;
  • Patients of childbearing potential (male or female) must use effective medical contraception during the study and for 6 months after the end of dosing;

Exclusion criteria

  • Active leptomeningeal disease or uncontrolled brain metastasis
  • Diagnosed with gastric or GEJ adenocarcinoma with positive HER2
  • Received other drugs in clinical study, major surgeries, or any other antitumor therapies within 4 weeks prior to the first dose of study treatment;
  • Patients with active hepatitis B or hepatitis C;
  • Patients have significant gastric bleeding
  • The presence of clinically uncontrollable third interspace fluid
  • Have clinically significant systemic diseases that may adversely affect the safety of the study;
  • Patients who may have poor compliance with the clinical study or have other factors based on which the investigator considers that the patients are not appropriate to patients in the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences — Beijing

Identifiers

NCT: NCT07609667 · SKB315-II-02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗